Aprea Therapeutics, Inc. (NASDAQ:APRE) SVP Gregory Alan Korbel Sells 32,960 Shares

Aprea Therapeutics, Inc. (NASDAQ:APRE) SVP Gregory Alan Korbel sold 32,960 shares of Aprea Therapeutics stock in a transaction on Monday, September 20th. The stock was sold at an average price of $4.97, for a total transaction of $163,811.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of NASDAQ APRE opened at $4.50 on Thursday. The company has a market cap of $95.34 million and a price-to-earnings ratio of -2.00. Aprea Therapeutics, Inc. has a 12 month low of $3.17 and a 12 month high of $30.99. The stock has a 50-day moving average price of $4.36 and a two-hundred day moving average price of $4.69.

Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Thursday, August 12th. The company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.01). As a group, equities research analysts forecast that Aprea Therapeutics, Inc. will post -1.77 EPS for the current year.

A number of equities analysts have commented on APRE shares. JPMorgan Chase & Co. cut shares of Aprea Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Friday, August 20th. HC Wainwright reduced their target price on shares of Aprea Therapeutics from $6.00 to $4.00 and set a “neutral” rating for the company in a research report on Monday, August 16th. Royal Bank of Canada reduced their target price on shares of Aprea Therapeutics from $6.00 to $5.00 and set a “sector perform” rating for the company in a research report on Friday, August 13th. Berenberg Bank cut shares of Aprea Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a research report on Monday, August 16th. Finally, Zacks Investment Research cut shares of Aprea Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 4th. Two equities research analysts have rated the stock with a sell rating and five have given a hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $4.15.

Several large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC grew its holdings in shares of Aprea Therapeutics by 292.9% during the second quarter. Virtu Financial LLC now owns 41,142 shares of the company’s stock worth $201,000 after purchasing an additional 30,671 shares during the last quarter. Morgan Stanley grew its holdings in shares of Aprea Therapeutics by 2.2% during the second quarter. Morgan Stanley now owns 1,019,776 shares of the company’s stock worth $4,975,000 after purchasing an additional 21,649 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Aprea Therapeutics during the second quarter worth about $162,000. PDT Partners LLC bought a new stake in shares of Aprea Therapeutics during the second quarter worth about $606,000. Finally, Royal Bank of Canada grew its holdings in shares of Aprea Therapeutics by 39.4% during the second quarter. Royal Bank of Canada now owns 21,150 shares of the company’s stock worth $104,000 after purchasing an additional 5,977 shares during the last quarter. Institutional investors own 30.73% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers.

Featured Story: Example of operating income, EBIT and EBITDA

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.